La Jolla Pharmaceutical (NASDAQ:LJPC) Expected to Announce Earnings of -$1.06 Per Share

Equities research analysts expect La Jolla Pharmaceutical (NASDAQ:LJPC) to post earnings of ($1.06) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for La Jolla Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.03) and the lowest estimate coming in at ($1.09). La Jolla Pharmaceutical reported earnings per share of ($1.73) in the same quarter last year, which suggests a positive year over year growth rate of 38.7%. The company is scheduled to report its next earnings results on Monday, March 2nd.

According to Zacks, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($4.44) per share for the current fiscal year, with EPS estimates ranging from ($4.50) to ($4.40). For the next year, analysts anticipate that the company will report earnings of ($2.90) per share, with EPS estimates ranging from ($3.75) to ($1.92). Zacks’ EPS averages are an average based on a survey of research analysts that follow La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative return on equity of 2,032.71% and a negative net margin of 683.88%. The firm had revenue of $5.71 million during the quarter, compared to the consensus estimate of $6.96 million.

Several research analysts have recently commented on the stock. BidaskClub lowered shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. ValuEngine raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. HC Wainwright decreased their price objective on shares of La Jolla Pharmaceutical from $27.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday. Chardan Capital reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a report on Thursday, August 15th. Finally, Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $14.17.

Shares of LJPC opened at $6.02 on Wednesday. The stock has a market cap of $170.99 million, a P/E ratio of -0.77 and a beta of 2.07. La Jolla Pharmaceutical has a 12-month low of $5.01 and a 12-month high of $16.44. The business’s fifty day moving average is $7.96 and its 200 day moving average is $8.55.

A number of institutional investors have recently modified their holdings of LJPC. Sio Capital Management LLC bought a new stake in La Jolla Pharmaceutical in the 2nd quarter valued at $12,121,000. Boxer Capital LLC bought a new position in shares of La Jolla Pharmaceutical during the 2nd quarter worth about $5,319,000. SG Americas Securities LLC lifted its holdings in shares of La Jolla Pharmaceutical by 394.8% during the 3rd quarter. SG Americas Securities LLC now owns 375,986 shares of the biopharmaceutical company’s stock worth $3,309,000 after acquiring an additional 299,995 shares during the period. VHCP Management III LLC lifted its holdings in shares of La Jolla Pharmaceutical by 24.7% during the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock worth $11,580,000 after acquiring an additional 248,298 shares during the period. Finally, Rock Springs Capital Management LP lifted its holdings in shares of La Jolla Pharmaceutical by 53.3% during the 2nd quarter. Rock Springs Capital Management LP now owns 425,000 shares of the biopharmaceutical company’s stock worth $3,931,000 after acquiring an additional 147,764 shares during the period.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Featured Article: Key terms to understand channel trading

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.